PYGL and metastatic neoplasm: As patient 0006 is male, there was no dosage compensation forMXRA5. Patient 0006’s primary and metastatic tumors had a splicing mutation in liver glycogen phosphorylase (PYGL, rs74464749), resulting in intron retention and expression of alternative splice variants in mRNA.